2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1710

Musculoskeletal Symptoms Preceding the Diagnosis of Psoriatic Arthritis – a Qualitative Exploration of the Patient Journey
Abstract Number: 158

Musculoskeletal Ultrasound Is a Sensitive Imaging Tool for the Assessment of Dynamic Changes of Bone Erosions in Inflammatory Arthritis: A Comparative Analysis with High-Resolution Peripheral Quantitatve Computed Tomography
Abstract Number: 2271

Mutation in Osteoprotegerin Gene: Early-Onset Osteoarthritis and Chondrocalcinosis in a US Family of Italian/German Ancestry
Abstract Number: 2430

Mutations in the Tyrosine-Protein Kinase Lyn Cause an Early-Onset Neutrophilic Vasculitis Syndrome
Abstract Number: 1824

Mycophenolate Mofetil Use Associates with Unique Biologic Changes in B Cell and T Regulatory Cell Pathways in SLE Patients
Abstract Number: 824

Mycophenolate Versus Placebo for the Treatment of Systemic Sclerosis-Related Interstitial Lung Disease
Abstract Number: 1393

Mycophenolic Acid Pharmacokinetics in Childhood-Onset Systemic Lupus Erythematosus Patients of Hispanic Ethnicity in a Single Center
Abstract Number: 6L

Myeloablative Autologous Transplantation of CD34+ -Selected Hematopoietic Stem Cells (HSCT) Vs Monthly Intravenous Cyclophosphamide (CYC) for Severe Scleroderma with Internal Organ Involvement: Outcomes of a Randomized North American Clinical Trial
Abstract Number: 1471

Myocardial 18f-Fluorodeoxyglucose (18F-FDG) Uptake in RA Patients without Clinical Cardiovascular Disease Is Higher Than in Controls and Decreases with Treatment
Abstract Number: 2055

Myocardial Abnormalities Are Associated with Corrected QT Interval in Patients with Rheumatoid Arthritis without Cardiac Symptoms Assessed Using Cardiac Magnetic Resonance Imaging
Abstract Number: 1494

Myocardial Structure, Function, and Fibrosis in Patients with Rheumatoid Arthritis and Matched Control Subjects
Abstract Number: 1819

Myocarditis in Systemic Lupus Erythematosus
Abstract Number: 475

N-3 Polyunsaturated Fatty Acids in Fat-1 Mice Attenuate Collagen Antibody-Induced Arthritis
Abstract Number: 2582

N-Acetylcysteine Regulates Osteoclastogenesis and Th17 Cell Differentiation in Rheumatoid Arthritis
Abstract Number: 2917

Nailfold Capillaroscopy and Mortality in Systemic Sclerosis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].